183 related articles for article (PubMed ID: 25993210)
1. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?
Scott DW
Am Soc Clin Oncol Educ Book; 2015; ():e458-66. PubMed ID: 25993210
[TBL] [Abstract][Full Text] [Related]
2. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
[TBL] [Abstract][Full Text] [Related]
3. Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma by Using a qPCR-based Gene Expression Assay on Formalin-Fixed Paraffin-Embedded Tissues.
Yan WH; Jiang XN; Wang WG; Sun YF; Wo YX; Luo ZZ; Xu QH; Zhou XY; Cao JN; Hong XN; Li XQ
Front Oncol; 2020; 10():803. PubMed ID: 32582543
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD
J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
6. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.
Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A
J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174
[TBL] [Abstract][Full Text] [Related]
7. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma.
Abdulla M; Hollander P; Pandzic T; Mansouri L; Ednersson SB; Andersson PO; Hultdin M; Fors M; Erlanson M; Degerman S; Petersen HM; Asmar F; Grønbaek K; Enblad G; Cavelier L; Rosenquist R; Amini RM
Am J Hematol; 2020 Jan; 95(1):57-67. PubMed ID: 31659781
[TBL] [Abstract][Full Text] [Related]
8. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
[TBL] [Abstract][Full Text] [Related]
9. Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.
Reinke S; Richter J; Fend F; Feller A; Hansmann ML; Hüttl K; Oschlies I; Ott G; Möller P; Rosenwald A; Stein H; Altenbuchinger M; Spang R; Klapper W
Virchows Arch; 2018 Sep; 473(3):341-349. PubMed ID: 29730836
[TBL] [Abstract][Full Text] [Related]
10. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
[TBL] [Abstract][Full Text] [Related]
11. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
Scott DW; Wright GW; Williams PM; Lih CJ; Walsh W; Jaffe ES; Rosenwald A; Campo E; Chan WC; Connors JM; Smeland EB; Mottok A; Braziel RM; Ott G; Delabie J; Tubbs RR; Cook JR; Weisenburger DD; Greiner TC; Glinsmann-Gibson BJ; Fu K; Staudt LM; Gascoyne RD; Rimsza LM
Blood; 2014 Feb; 123(8):1214-7. PubMed ID: 24398326
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR.
Xue X; Zeng N; Gao Z; Du MQ
Lab Invest; 2015 Jan; 95(1):113-20. PubMed ID: 25418578
[TBL] [Abstract][Full Text] [Related]
13. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.
Perfecto-Avalos Y; Garcia-Gonzalez A; Hernandez-Reynoso A; Sánchez-Ante G; Ortiz-Hidalgo C; Scott SP; Fuentes-Aguilar RQ; Diaz-Dominguez R; León-Martínez G; Velasco-Vales V; Cárdenas-Escudero MA; Hernández-Hernández JA; Santos A; Borbolla-Escoboza JR; Villela L
J Transl Med; 2019 Jun; 17(1):198. PubMed ID: 31185999
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
15. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
Barton S; Hawkes EA; Wotherspoon A; Cunningham D
Oncologist; 2012; 17(12):1562-73. PubMed ID: 23086691
[TBL] [Abstract][Full Text] [Related]
16. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
17. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
[TBL] [Abstract][Full Text] [Related]
18. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
19. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
20. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma.
Linton K; Howarth C; Wappett M; Newton G; Lachel C; Iqbal J; Pepper S; Byers R; Chan WJ; Radford J
J Mol Diagn; 2012; 14(3):223-32. PubMed ID: 22446084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]